LXRXLEXICON PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $50M
- 730% YoY
- Operating margin
- -98.2%
- 97% YoY
- EBITDA
- −$48M
- 75% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$35M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired25% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-3% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear18% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1M | $6M | $50M | 730% |
| Operating income | −$87M | −$101M | −$172M | −$197M | −$49M | 75% |
| Net income | −$88M | −$102M | −$177M | −$200M | −$50M | 75% |
| Operating cash flow | −$87M | −$89M | −$162M | −$179M | −$68M | 62% |
| Capex | $1M | $1M | $470K | $1M | $0 | 100% |
| Stock-based comp | $11M | $12M | $14M | $13M | $13M | 7.3% |
| Buybacks | $3M | $864K | $824K | $2M | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.